Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 5 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Blueprint Medicines Corporation is managing active matters within the Biotechnology and Pharmaceuticals technology area. The portfolio currently includes 6 pending office actions, which are distributed among 6 distinct examiners. This one-to-one distribution indicates that the company is receiving feedback from a range of perspectives within the USPTO. The use of 6 distinct examiners suggests that no single individual's tendencies will dominate the portfolio's overall success.
The active applications are spread across 4 distinct art units, reflecting a technical footprint within the biotechnology sector. SHIM, DAVID M. is identified as the busiest examiner, though they are only responsible for 1 pending office action. This parity across the examiner pool means that the company must manage 6 different prosecution styles simultaneously. For practitioners, this requires a strategy that can adapt to the requirements of 4 different art units. The presence of 6 pending office actions across this group of examiners highlights the task of maintaining consistency in claim language and disclosure across the Biotechnology and Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (12%) |
| §112 only | 1 (12%) |
| Double-patenting only | 2 (25%) |
| Double-patenting + other | 3 (38%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIM, DAVID M. | 1 | 58.3% | +58.3% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
| MARTIN, KEVIN STEPHEN | 1 | 77.2% | +23.2% |
| ENGLISH, CONNOR KENNEDY | 1 | 60.0% | +51.3% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.5% | +49.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031688 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | TOWNSLEY, SARA ELIZABETH | 49d overdue |
| 18710715 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | MARTIN, KEVIN STEPHEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031688 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | TOWNSLEY, SARA ELIZABETH | 49d overdue |
| 18573222 | SALT AND CRYSTAL FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | ENGLISH, CONNOR KENNEDY | 26d |
| 18853933 | EGFR INHIBITORS | SHIM, DAVID M. | — |
| 18849277 | BLU-945 IN COMBINATION WITH OSIMERTINIB FOR THE TREATMENT OF NON-SMALL-CELL LUNG CANCER | HEITMEIER, KENDALL NICOLE | — |
| 18710715 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | MARTIN, KEVIN STEPHEN | — |
| 18572348 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | O DELL, DAVID K | — |
| 18572382 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | SZNAIDMAN, MARCOS L | — |
| 18033931 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | HERNANDEZ, JACKSON J | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1625 | 1 |
| 1628 | 1 |
| 1627 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18853933 | EGFR INHIBITORS | SHIM, DAVID M. | — | §112 | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18849277 | BLU-945 IN COMBINATION WITH OSIMERTINIB FOR THE TREATMENT OF NON-SMALL-CELL LUNG CANCER | HEITMEIER, KENDALL NICOLE | 1621 | §103DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18710715 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | MARTIN, KEVIN STEPHEN | — | §102§103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18573222 | SALT AND CRYSTAL FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | ENGLISH, CONNOR KENNEDY | 1625 | DP | Non-Final OA | 26d | Pending | Dec 21, 2023 |
| 18572348 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | O DELL, DAVID K | 1621 | §103DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18572382 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | SZNAIDMAN, MARCOS L | 1628 | §112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18033931 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | HERNANDEZ, JACKSON J | 1627 | DP | Final Rejection | — | Pending | Apr 26, 2023 |
| 18031688 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | TOWNSLEY, SARA ELIZABETH | 1629 | §103 | Final Rejection | 49d overdue | Pending | Apr 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial